$Arcturus Therapeutics(ARCT.US)https://mp.weixin.qq.com/s/C-FJ2P9SyDpT5Kzkbirwrw In-depth analysis of the root cause of ARCT's misjudgment, the argument of ARCT032 trial failure is invalid - independent thinking and in-depth analysis are the keys to successful investment. Recently, ARCT (Arcturus Therapeutics) stock price experienced a significant drop, with a single-day decline of up to 60%. We pointed out in a previous article that this was clearly a misjudgment, and the root cause of this misjudgment lies in the market interpreting the ARCT032 Phase II interim data as a failure, leading to unnecessary panic.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
